Surgical management of the axilla has evolved considerably in recent years, with a strong focus on de-escalation to minimise morbidity whilst maintaining oncological outcomes. Current trials will focus on the omission of Sentinel node biopsy in select groups of patients, while axillary lymph node dissection will be reserved for those with more aggressive disease.
Keyphrases
- sentinel lymph node
- lymph node
- end stage renal disease
- rectal cancer
- ejection fraction
- chronic kidney disease
- newly diagnosed
- radical prostatectomy
- ultrasound guided
- neoadjuvant chemotherapy
- early stage
- prognostic factors
- peritoneal dialysis
- prostate cancer
- randomized controlled trial
- patient reported outcomes
- metabolic syndrome
- skeletal muscle